Objective: To assess the long-term efficacy of radiofrequency ablation (RFA) and percutaneous ethanol (EtOH) injection treatment of local recurrence or focal distant metastases of well-differentiated thyroid cancer (WTC).

Background: RFA and EtOH injection techniques are new minimally invasive surgical alternatives for treatment of recurrent WTC. We report our experience and long-term follow-up results using RFA or EtOH ablation in treating local recurrence and distant focal metastases from WTC.

Methods: Twenty patients underwent treatment of biopsy-proven recurrent WTC in the neck. Sixteen of these patients had lesions treated by ultrasound-guided RFA (mean size, 17.0 mm; range, 8-40 mm), while 6 had ultrasound-guided EtOH injection treatment (mean size, 11.4 mm; range, 6-15 mm). Four patients underwent RFA treatment of focal distant metastases from WTC. Three of these patients had CT-guided RFA of bone metastases (mean size, 40.0 mm; range, 30-60 mm), and 1 patient underwent RFA for a solitary lung metastasis (size, 27 mm). Patients were then followed with routine ultrasound, I whole body scan, and/or serum thyroglobulin levels for recurrence at the treatment site.

Results: No recurrent disease was detected at the treatment site in 14 of the 16 patients treated with RFA and in all 6 patients treated with EtOH injection at a mean follow-up of 40.7 and 18.7 months, respectively. Two of the 3 patients treated for bone metastases are free of disease at the treatment site at 44 and 53 months of follow-up, respectively. The patient who underwent RFA for a solitary lung metastasis is free of disease at the treatment site at 10 months of follow-up. No complications were experienced in the group treated by EtOH injection, while 1 minor skin burn and 1 permanent vocal cord paralysis occurred in the RFA treatment group.

Conclusions: RFA and EtOH ablation show promise as alternatives to surgical treatment of recurrent WTC in patients with difficult reoperations. Further long-term follow-up studies are necessary to determine the precise role these therapies should play in the treatment of recurrent WTC.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1602167PMC
http://dx.doi.org/10.1097/01.sla.0000217685.85467.2dDOI Listing

Publication Analysis

Top Keywords

etoh injection
20
treatment recurrent
16
recurrent wtc
16
treatment
13
injection treatment
12
rfa etoh
12
underwent rfa
12
treatment site
12
patients treated
12
rfa
11

Similar Publications

Optimized chelator and nanoparticle strategies for high-activity Pd-loaded biodegradable brachytherapy seeds.

EJNMMI Radiopharm Chem

December 2024

The Hevesy Laboratory, DTU Health Technology, Frederiksborgvej 399, 4000, Roskilde, Denmark.

Background: Brachytherapy (BT) is routinely used in the treatment of various cancers. Current BT relies on the placement of large sources of radioactivity at the tumor site, requiring applicators that may cause local traumas and lesions. Further, they suffer from inflexibility in where they can be placed and some sources reside permanently in the body, causing potential long-term discomfort.

View Article and Find Full Text PDF

Background: In rodents, third-trimester-equivalent alcohol exposure (TTAE) produces significant deficits in hippocampal-dependent memory processes such as contextual fear conditioning (CFC). The present study sought to characterize changes in both behavior and Fos neurons following CFC in ethanol (EtOH)-treated versus saline-treated mice using TRAP2:Ai14 mice that permanently label Fos neurons following a tamoxifen injection. We hypothesized that TTAE would produce long-lasting disruptions to the networks engaged following CFC with a particular emphasis on the limbic memory system.

View Article and Find Full Text PDF

Mecamylamine Reverses the Effects of Cytisine on the Oral Self-administration of Ethanol in Rats.

Basic Clin Neurosci

July 2024

Faculty of Higher Studies Iztacala, Universidad Nacional Autónoma de México, Mexico City, Mexico.

Article Synopsis
  • The study investigates how nicotinic acetylcholine receptors (nAchRs) in the brain regions VTA and nAcc influence alcohol self-administration in rats.
  • Male Wistar rats were trained to press a lever for ethanol and then received injections of either nAchR antagonist mecamylamine or agonist cytisine to assess their effects on drinking behavior.
  • Results indicated that mecamylamine decreased and cytisine increased ethanol self-administration, suggesting that nAchRs play a significant role in modulating alcohol consumption in rats.
View Article and Find Full Text PDF

There are limited options for primary prevention of breast cancer (BC). Experimental procedures to locally prevent BC have shown therapeutic efficacy in animal models. To determine the suitability of FDA-approved iodine-containing and various metal-containing (bismuth, gold, iodine, or tantalum) preclinical nanoparticle-based contrast agents for image-guided intraductal (ID) ablative treatment of BC in rodent models, we performed a prospective longitudinal study to determine the imaging performance, local retention and systemic clearance, safety profile, and compatibility with ablative solution of each contrast agent.

View Article and Find Full Text PDF

Rationale: Although the mesocorticolimbic dopamine (DA) system is the main neurochemical substrate that regulates the addictive and reinforcing effects of ethanol (EtOH), other neurotransmitter systems, such as the acetylcholine (Ach) system, modulate DAergic function in the nucleus accumbens (nAcc). Previously, we reported that intra-nAcc administration of the nicotinic Ach receptor agonist cytisine increased oral EtOH self-administration. GABAB receptors in the nAcc are expressed in DAergic terminals, inhibit the regulation of DA release into the nAcc, and could modulate the effects of cytisine on oral EtOH self-administration.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!